Ranger™ and Ranger™ SL (OTW) DCB) in China

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.

Also called NCT02944071

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 123 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02944071
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02944071. Allocation not applicable; no masking; primary purpose treatment. Start 2016-11-24 (actual); primary completion 2020-12-22 (actual). Results posted on 2022-03-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranger™ and Ranger™ SL (OTW) DCB) in China
Condition
Femoropopliteal Artery Lesions
Intervention (Device)
Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct02944071
Content hash
19119fd8d5fd1904ba70ba2b4b307544af93e3d9e965ed9fe4d7a39479d6a262